Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Errante
D
D
Bernardi
D
D
Bianco
A
A
De Nardi
S
S
Salvagno
L
L
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D051379:Mice; D000069283:Rituximab; D012878:Skin Neoplasms / Q000188:drug therapy*; D014581:Urticaria / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab